In a significant development, BioArctic's partner Eisai announced that the Department of Health in Hong Kong has approved Leqembi (lecanemab) for the treatment of Alzheimer's disease. This approval comes after the successful Phase 3 Clarity AD study, which demonstrated statistically significant results in slowing cognitive decline. Hong Kong is now the fifth country to approve Leqembi, following the United States, Japan, China, and South Korea. Leqembi is designed to target amyloid-beta aggregates, which are believed to contribute to the progression of Alzheimer's disease. BioArctic will be responsible for commercializing Leqembi in the Nordic region, pending European approval, and will receive a 9% royalty on global sales [d0792c1f].
This approval in Hong Kong expands the availability of Leqembi as a treatment option for Alzheimer's disease, providing hope for patients and their families. Alzheimer's disease is a devastating neurodegenerative disorder that affects millions of people worldwide. It is characterized by cognitive decline, memory loss, and impaired daily functioning. The approval of Leqembi in Hong Kong underscores the growing recognition of the importance of developing effective treatments for this debilitating condition. With the approval of Leqembi in multiple countries, there is renewed optimism in the field of Alzheimer's research and the potential for improving the lives of those affected by the disease [d0792c1f].